<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39466880</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.</ArticleTitle><Pagination><StartPage>e1012650</StartPage><MedlinePgn>e1012650</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012650</ELocationID><Abstract><AbstractText>The recurring spillover of pathogenic coronaviruses and demonstrated capacity of sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need to better understand immune responses to this virus family. For this purpose, we characterized the functional breadth and potency of antibodies targeting the receptor binding domain (RBD) of the spike glycoprotein that exhibited cross-reactivity against SARS-CoV-2 variants, SARS-CoV-1 and sarbecoviruses from diverse clades and animal origins with spillover potential. One neutralizing antibody, C68.61, showed remarkable neutralization breadth against both SARS-CoV-2 variants and viruses from different sarbecovirus clades. C68.61, which targets a conserved RBD class 5 epitope, did not select for escape variants of SARS-CoV-2 or SARS-CoV-1 in culture nor have predicted escape variants among circulating SARS-CoV-2 strains, suggesting this epitope is functionally constrained. We identified 11 additional SARS-CoV-2/SARS-CoV-1 cross-reactive antibodies that target the more sequence conserved class 4 and class 5 epitopes within RBD that show activity against a subset of diverse sarbecoviruses with one antibody binding every single sarbecovirus RBD tested. A subset of these antibodies exhibited Fc-mediated effector functions as potent as antibodies that impact infection outcome in animal models. Thus, our study identified antibodies targeting conserved regions across SARS-CoV-2 variants and sarbecoviruses that may serve as therapeutics for pandemic preparedness as well as blueprints for the design of immunogens capable of eliciting cross-neutralizing responses.</AbstractText><CopyrightInformation>Copyright: © 2024 Ruiz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Felicitas</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>William B</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lilly</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baharani</LastName><ForeName>Viren A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Laboratory of Retrovirology, The Rockefeller University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depierreux</LastName><ForeName>Delphine M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chohan</LastName><ForeName>Vrasha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Ashley L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guenthoer</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsen Iv</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Helen Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieniasz</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Laboratory of Retrovirology, The Rockefeller University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, The Rockefeller University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Côté</LastName><ForeName>Marceline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>Tyler N</ForeName><Initials>TN</Initials><Identifier Source="ORCID">0000-0001-6713-6904</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overbaugh</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0239-9444</Identifier><AffiliationInfo><Affiliation>Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>I have read the journal’s policy and the authors of this manuscript have the following competing interests: J.O. is a consultant for Aerium Therapeutics, Inc. J.O. and J.G are listed on a patent application (22-173-US-PSP2) and license agreement with Aerium Therapeutics, Inc. for C68.61. H.Y.C reported consulting with Ellume, Merck, Abbvie, Pfizer, Medscape, Vindico, and the Bill and Melinda Gates Foundation. She has received research funding from Gates Ventures, and support and reagents from Ellume and Cepheid outside of the submitted work. T.N.S. consults for Apriori Bio and Vir Biotechnology on deep mutational scanning. The lab of T.N.S. has received sponsored research agreements unrelated to the present work from Vir Biotechnology, Aerium Therapeutics, Inc. and Invivyd, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>13</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39466880</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012650</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-24-00874</ArticleId></ArticleIdList></PubmedData></PubmedArticle>